Target intelligence / Profile preview

Obg-like ATPase 1 (OLA1)

Target
OLA1
Molecular classification
Enzyme, P-loop NTPase, Obg family, Translation factor-related class
01

Overview

Obg-like ATPase 1 (OLA1) is an evolutionarily conserved ATPase and GTPase belonging to the Obg family of P-loop NTPases, more specifically the translation factor-related class (TRAFAC)[1][2][3]. OLA1 performs essential roles in eukaryotic cells including suppression of protein synthesis by inhibiting ternary complex (TC) formation during translation initiation, regulation of the integrated stress response (ISR) via direct interaction with eIF2, modulation of cell cycle progression, and involvement in DNA damage responses and cytoskeleton organization[2][3]. OLA1 is implicated in cancer, both as a negative regulator (its depletion enhances tumor growth and metastasis) and as a prognostic biomarker in certain tumors, notably breast cancer[3]. The enzyme exhibits higher affinity for ATP than GTP and displays both ATPase and GTPase activities, making it an exceptional example of altered nucleotide specificity within a distinct protein family[1]. No direct therapeutic drugs are available or documented for this molecular target.

Other names
GTPBP9DOC45PTD004DNA damage-regulated overexpressed in cancer 45GTP-binding protein 9GBP45homologous yeast-44.2 protein
02

Mechanism of action

Inhibition of ATPase/GTPase activity; Modulation of integrated stress response via eIF2 interaction; Regulation of translation and cell survival pathways

03

Biological functions

Regulation of protein synthesisCell cycle controlRegulation of apoptosisIntegrated stress response (ISR)Negative regulation of antioxidant responseDNA damage responseCell motility and cytoskeleton organization
04

Disease associations

CancerOther
05

Safety considerations

Potential for increased tumor growth and metastasis with OLA1 inhibition (as shown in knockdown studies)Regulation of fundamental cellular processes (protein synthesis, cell cycle) suggests off-target or systemic adverse effects might be significant if pharmacologically targeted
06

Biomarkers

Lower expression of OLA1 correlates with worse outcomes in breast cancerOverexpression or depletion may serve as a biomarker for cancer prognostics, especially for ISR-deficiency status

Beyond the preview

Go deeper on Obg-like ATPase 1 (OLA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Obg-like ATPase 1 (OLA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call